| Document |
Document Title |
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/005075A1 |
The present invention relates to the use of at least one phenolically substituted sugar derivative as a stabiliser of organic materials, in particular plastics, against oxidative, thermal and/or actinic degradation. The present invention...
|
|
WO/2020/260351A1 |
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.
|
|
WO/2020/255989A1 |
Provided is a novel compound which is contained in a watermelon young fruit and has an antioxidative effect. A novel compound which is contained in a watermelon young fruit and is represented by formula (1) or (2) has an antioxidative ...
|
|
WO/2020/256084A1 |
A crystal of a compound represented by formula 5. In formula 5, R1 represents a hydroxyl protecting group, and R2 represents a leaving group.
|
|
WO/2020/254369A1 |
Disclosed herein are new O-biphenyl- and O-phenylheteroaryl- mannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subject...
|
|
WO/2020/252254A1 |
The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivati...
|
|
WO/2020/252294A1 |
The application relates to immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of F...
|
|
WO/2020/244253A1 |
Disclosed is an application of a small molecule compound or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor metastasis drug. The structure of the compound is as shown in formula (I). The small molecule comp...
|
|
WO/2020/247480A1 |
Described herein are composition of ascarosides, methods of using them, and the like for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of b...
|
|
WO/2020/243815A1 |
A tetrasaccharide of formula I and a method of production thereof are provided. Furthermore, a conjugate comprising the tetrasaccharide and a molecule attached to the tetrasaccharide, preferably via its amine group, is also provided. Com...
|
|
WO/2020/244518A1 |
The present invention provides a compound with benzyloxy aromatic ring structure represented by general formula (I), a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical c...
|
|
WO/2020/244483A1 |
Provided are novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the...
|
|
WO/2020/242796A1 |
Assays and methods for diagnosing whether a subject has a cardiovascular disease (CVD) by measuring the concentrations of nitric oxide [NO] and peroxynitrite [ONOO- ] stimulated by the different subclasses of LDL in one or more cells of ...
|
|
WO/2020/239096A1 |
A new class of antibacterial aminoglycoside derivatives, pharmaceutical compositions containing such compounds, and application thereof in the preparation of drugs for treating diseases related to bacterial infections. Specifically discl...
|
|
WO/2020/237836A1 |
Provided is a method for preparing 4-idarubicin hydrochloride. The method comprises the step of preparing compound B into compound C in the presence of tetrabutyl ammonium halide, and the 4-idarubicin hydrochloride can be further obtaine...
|
|
WO/2020/239135A1 |
The present invention relates to a high anticoagulation activity compound, a preparation method and an application, said compound being formed from a monosaccharide unit D, a monosaccharide unit E, a 6-position carbon oxygen-substituted ...
|
|
WO/2020/234270A1 |
The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5- trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10
,10a- octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-car
boxylic acid with the fo...
|
|
WO/2020/236621A1 |
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administ...
|
|
WO/2020/234208A1 |
The invention comprises a process for the preparation of a GalNAc phosphoramidite epimer of the formula (I), wherein R1 is a hydroxy protecting group, n is an integer from 0 to 10 and m is an integer from 0 to 20, corresponding enantiome...
|
|
WO/2020/236684A1 |
Stevia flavor compositions comprising a high level of reb audioside AM (Reb AM) are decribed. These compositions are flavors with modifying properties, or FMPs. Using an FMP, certain flavor notes in a consumable product may be enhanced, ...
|
|
WO/2020/233680A1 |
An siRNA which inhibits kininogen (KNG) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide. The siRNA contains a s...
|
|
WO/2020/232534A1 |
Low permeability across the outer membrane is a major reason why most antibiotics are ineffective against Gram-negative bacteria. Agents that permeabilize the outer membrane are typically toxic at their effective concentrations. Here, we...
|
|
WO/2020/231333A1 |
Provided herein are compounds, extracted from Wrightia antidysenterica, that are potent inhibitors of tyrosinase and melanogenesis, which can be used as skin whitening agents. Provided also are compositions comprising the compounds and m...
|
|
WO/2020/105054A9 |
Modified aminoglycoside compounds represented by Formula I as defined and described in the specification are provided. The modified aminoglycosides feature a diamine-containing functional moiety at one or more of positions 3', 4' and 6'....
|
|
WO/2020/218382A1 |
It has been expected to develop a novel GLP-1 secretagogue which promotes the secretion of GLP-1. The present invention provides a GLP-1 secretagogue characterized by comprising 0.4-4,440 ppm of a steviol glycoside having a structure to ...
|
|
WO/2020/219417A1 |
Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, mult...
|
|
WO/2020/219419A1 |
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by se lectin binding are described herein. For example, multimeric selectin modulators and their use are described, wherein the multimeric select...
|
|
WO/2020/213891A1 |
The present application relates to a sweetener composition comprising a fructose-transferred steviol glycoside, and a method for improving sweetness of a steviol glycoside comprising a step of converting the steviol glycoside to a fructo...
|
|
WO/2020/214901A1 |
Compositions and methods for protecting an organism from a pathogen are disclosed.
|
|
WO/2020/210907A1 |
The present disclosure relates to processes for recovering valuable products from Fabaceae family plant fractions, in particular from Medicago sativa ssp. The processes disclosed herein include processes for obtaining macrofibers, microf...
|
|
WO/2020/205978A1 |
Compositions comprising brazzein (or analogs thereof), including sweetener compositions, flavor modifying compositions, sweetened compositions, flavor modified compositions are disclosed. Also disclosed are methods of improving the tempo...
|
|
WO/2020/198878A1 |
The present application provides compounds, compositions and methods to reduce, alleviate or treat various enteric diseases and disorders, such as inflammatory bowel disease. The compounds are xyloglucan-containing prodrugs, referred to ...
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
|
WO/2020/189734A1 |
Provided is a compound or salt thereof represented by formula (I) below [In formula (I), R1 represents –COOH or –CY1Y2OH (where, Y1 and Y2 each represent a hydrogen atom or a detectable marker), A1 represents a sugar or an aglycone, ...
|
|
WO/2020/183442A2 |
The present disclosure relates to phenylpropanoid saccharide esters, methods for the synthesis of libraries of phenylpropanoid saccharide esters with different degree and place of substitution in the sugar core, and their use as antimicr...
|
|
WO/2020/177568A1 |
The present invention relates to an LL-D49194α1 analog, a preparation method therefor and an application thereof. Specifically, provided by the present invention is a deglycosylated and demethylated LL-D49194α1 analog. The obtained LL-...
|
|
WO/2020/178053A1 |
Phenol derivatives of general formula (I) and (II), wherein meanings of the substituents are indicated in the description, their pharmaceutically acceptable salts, together with the processes for their preparation, their use as antimicro...
|
|
WO/2020/172755A1 |
Disclosed are compounds of formula (I): Yp–X–L2–Z, (I) or a salt thereof, where p is 1 to 5; X is a monosaccharide; each Y is independently –L1–T, H, protecting group, optionally substituted hydrocarbon, or optionally substitut...
|
|
WO/2020/175648A1 |
The present invention is a diblock-type oligomer, which has a pyranose block and an alkyl pyranose block and is represented by formula (I) in figure 1 (in formula (I), each R1 independently represents a methyl or an ethyl, m is 1.0 to 3....
|
|
WO/2020/176470A1 |
Provided is a method of treating benign prostatic hyperplasia (BPH) in a patient. Also provided is a method of inhibiting non- adrenergic contraction of a smooth muscle. Additionally provided is a method of inhibiting proliferation of hu...
|
|
WO/2020/176602A1 |
Mogrosides containing non-glucose glycosides are provided herein. Compositions, including consumables comprising the novel mogrosides described herein, are also provided.
|
|
WO/2020/168312A1 |
Methods of preparing highly purified steviol glycosides. The methods include utilizing enzyme preparations and recombinant microorganisms for converting various starting compositions to target steviol glycosides. The highly purified stev...
|
|
WO/2020/163693A1 |
Reformulations of gentamicin for treatment of infections are provided with the goal to reduce current side effects such as ototoxicity, while maintaining antimicrobial activity. The reformulation is a mixture of three of the C-components...
|
|
WO/2020/157494A1 |
Described herein are compounds comprising a dimer of dehydrosalicortin or a derivative, homologue, stereoisomer, prodrug or pharmaceutical salt thereof. In particular embodiments, the dimer is a result of a Diels-Alder reaction. Also des...
|
|
WO/2020/158995A1 |
The present invention provides a novel rhamnolipid compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. A novel rhamnolipid compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof,...
|
|
WO/2020/155519A1 |
Disclosed is a synthesis of a Helicobacter pylori O2 serotype O-antigen oligosaccharide compound, which belongs to the field of organic synthesis. The invention obtains, through chemical synthesis, Helicobacter pylori O2 serotype O-antig...
|
|
WO/2020/155494A1 |
A preparation method of a sweetener composition comprises the following steps: acquiring minced leaves of Rubus suavissimus; using water as a solvent to perform extraction; removing phenolic hydroxyl group-containing components; performi...
|
|
WO/2020/148641A1 |
The present invention relates to a process for preparation of 2-Amino-5-hydroxypropiophenone, a key intermediate for the synthesis of camptothecin analogs including 7-Ethyl-10-hydroxycamptothecin (SN-38).
|
|
WO/2020/135898A1 |
The present invention provides synthetic oligosaccharide fragments from the terminal pentasaccharide of the lipooligosaccharide of Bordetella pertussis, and a method for obtaining the synthetic oligosaccharides fragments and conjugates f...
|
